Evaluation of the role of MxA and ISGylation in chemosensitivity in oesophageal cancer

Robert Hayes

Many oesophageal cancers develop resistance to the drugs currently used to treat this disease. This allows the cancer cells to survive and the cancer can come back again at variable times after the initial treatment. Research already performed by this group has identified genetic differences between cancer cells that respond well to treatment and those that do not. This project will examine how the genes involved can re-program cancers and influence their response to treatment. We have already identified a novel gene pathway that can dramatically improve how cancer cells respond to chemotherapy. Understanding these novel genes and how they regulate death and survival in cancer cells will enable us to develop more specific anti-cancer agents for the future. The overall aim of this project is to identify new ways of targeting drug-resistant oesophageal cancers so that chemotherapeutic regimes can be improved and recurrent diseases eliminated in cancer patients.

Start year:
End year:
Principal Investigator:
Dr Sharon McKenna
PhD Scholar:
Robert Hayes
Grant funding:
Breakthrough Cancer Research charity partner in the MRCG-HRB Joint-funding scheme
Cancer type:
Linked Breakthrough Research Priorities: 
1, 3, 4, 5

View More